Drug intelligence / Profile preview

IELMAG3

Development stage
Unknown
Lead developer
ROTOP Pharmaka
Modality
Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous
01

Overview

IELMAG3 is a diagnostic radiopharmaceutical kit containing the chelating agent mertiatide (mercaptoacetyltriglycine, MAG3) that is radiolabelled with technetium-99m to produce 99mTc-mertiatide for renal imaging and function studies.[3][4][9] After intravenous administration of the labelled product, 99mTc-mertiatide is rapidly distributed in the extracellular fluid and almost entirely cleared by tubular secretion in the kidneys, enabling dynamic renography to assess renal perfusion, tubular function, drainage, and urinary tract obstruction.[3][4][9] IELMAG3 is supplied as a two-vial kit (mertiatide plus excipients and a stannous-containing vial for reduction) that is reconstituted with sodium pertechnetate (99mTc) solution immediately before use and is indicated for diagnostic use only.[3][4][9]

Brand names
IELMAG3IELMAG-3IELMAG 3
02

Targets

SLC22A8 (Organic anion transporter 3)OAT1 (Organic anion transporter 1)

Beyond the preview

Go deeper on IELMAG3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IELMAG3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call